SLU-PP-332 research guide
Synthetic small-molecule estrogen-related receptor (ERR) agonist
SLU-PP-332 research explained through ERR receptor assays, muscle-cell measurements and mouse metabolic studies, without treating preclinical findings as product claims.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
SLU-PP-332 is a synthetic small molecule characterised as an agonist of the estrogen-related nuclear receptors ERRα, ERRβ and ERRγ. The original study reported the greatest potency at ERRα among the three tested subtypes. It is not a peptide or a growth-hormone analogue. Its research context concerns receptor-regulated metabolic programmes, so the exact ERR target and experimental model should accompany a claim.
02 · Evidence position
What the literature can support
The selected primary papers report receptor assays, skeletal-muscle-cell experiments and mouse studies. Cellular respiration, gene expression and whole-animal endpoints are different levels of evidence. The term exercise mimetic describes the authors’ experimental comparison; it does not establish an exercise substitute or a benefit for people. The papers do not verify independently supplied catalogue material.
03 · Study-level map
Evidence and its limits
Which receptor and cellular findings were reported?
The 2023 paper characterised SLU-PP-332 across ERRα, ERRβ and ERRγ assays and reported increased mitochondrial function and respiration in a skeletal-muscle cell line. Mouse experiments investigated oxidative muscle characteristics and exercise endurance.
Limit: The cell and animal systems define the observations. A name on a vial does not establish comparable receptor activity, exposure or performance.
What did the metabolic follow-up examine?
The 2024 paper assessed SLU-PP-332 in diet-induced-obese and ob/ob mouse models. It reported changes in energy expenditure and fatty-acid oxidation, accompanied by reduced fat-mass accumulation and improved insulin sensitivity in the tested models.
Limit: This is mouse evidence, not a human trial. Outcomes for the tested preparation should not be generalised to other ERR agonists or commercial powders.
04 · Analytical context
Questions a batch record should answer
- 01Do chemical identity measurements match SLU-PP-332 rather than another ERR agonist or a product with a similar code?
- 02Are purity, quantitative content and any receptor activity measurements identified separately with their methods and reporting basis?
- 03Does the offered material have a defined specification and a traceable relationship to any tested sample or analytical report?
05 · Boundary conditions
What this record does not establish
- No matching APS analytical report for SLU-PP-332 5mg was verified for this guide.
- The selected studies do not establish human efficacy, long-term safety or the suitability of a supplier powder for a particular assay.
- A shared research topic does not establish that distinct small molecules and peptides are interchangeable.
Sources checked
- 1.SLU-PP-332: ERR agonism, muscle-cell responses and mouse endurance
Billon et al. — ACS Chemical Biology · 2023 · Primary study
- 2.A synthetic ERR agonist in mouse metabolic-syndrome models
Billon et al. — Journal of Pharmacology and Experimental Therapeutics · 2024 · Primary study